Abstract:Chemotherapy-induced peripheral neuropathy (CIPN) is the most common off-target adverse effects caused by various chemotherapeutic agents, such as cisplatin, oxaliplatin, paclitaxel, vincristine and bortezomib. CIPN is characterized by a substantial loss of primary afferent sensory axonal fibers leading to sensory disturbances in patients. An estimated of 19–85% of patients developed CIPN during the course of chemotherapy. The lack of preventive measures and limited treatment options often require a dose reduction or even early termination of life-saving chemotherapy, impacting treatment efficacy and patient survival. In this Review, we summarized the current understanding on the pathogenesis of CIPN. One prominent change induced by chemotherapeutic agents involves the disruption of neuronal cytoskeletal architecture and axonal transport dynamics largely influenced by the interference of microtubule stability in peripheral neurons. Due to an ineffective blood-nerve barrier in our peripheral nervous system, exposure to some chemotherapeutic agents causes mitochondrial swelling in peripheral nerves, which lead to the opening of mitochondrial permeability transition pore and cytochrome c release resulting in degeneration of primary afferent sensory fibers. The exacerbated nociceptive signaling and pain transmission in CIPN patients is often linked the increased neuronal excitability largely due to the elevated expression of various ion channels in the dorsal root ganglion neurons. Another important contributing factor of CIPN is the neuroinflammation caused by an increased infiltration of immune cells and production of inflammatory cytokines. In the central nervous system, chemotherapeutic agents also induce neuronal hyperexcitability in the spinal dorsal horn and anterior cingulate cortex leading to the development of central sensitization that causes CIPN. Emerging evidence suggests that the change in the composition and diversity of gut microbiota (dysbiosis) could have direct impact on the development and progression of CIPN. Collectively, all these aspects contribute to the pathogenesis of CIPN. Recent advances in RNA-sequencing offer solid platform for in silico drug screening which enable the identification of novel therapeutic agents or repurpose existing drugs to alleviate CIPN, holding immense promises for enhancing the quality of life for cancer patients who undergo chemotherapy and improve their overall treatment outcomes.

Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach

The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy

Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development

Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neuropathy

Lysosomal Dysfunction in Schwann Cells is Involved in Bortezomib-Induced Peripheral Neurotoxicity

Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients

Neuronal toxicity and recovery from early bortezomib-induced neuropathy: targeting the blood nerve barrier but not the dorsal root ganglion

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients

Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy

Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back

Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues

Baseline Peripheral Neuropathy Was Associated with Age and a Prognostic Factor in Newly Diagnosed Multiple Myeloma Patients.

Emerging Trends in Understanding Chemotherapy-Induced Peripheral Neuropathy

Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain

Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma

Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

Update on the optimal use of bortezomib in the treatment of multiple myeloma

Biological Mediators and Partial Regulatory Mechanisms on Neuropathic Pain Associated With Chemotherapeutic Agents

Chemotherapy-induced peripheral neuropathy: where are we now?

Advances in Peripheral Neuropathy Induced by Chemotherapy and Its Prevention and Treatment